Fusion Pharmaceuticals - FUSN Stock Forecast, Price & News

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Fusion Pharmaceuticals in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" FUSN shares.
View FUSN analyst ratings or view top-rated stocks.

5 brokerages have issued 12-month target prices for Fusion Pharmaceuticals' stock. Their FUSN share price forecasts range from $19.00 to $19.00. On average, they predict the company's share price to reach $19.00 in the next year. This suggests a possible upside of 789.9% from the stock's current price.
View analysts price targets for FUSN or view top-rated stocks among Wall Street analysts.

Fusion Pharmaceuticals' stock was trading at $4.17 on January 1st, 2022. Since then, FUSN shares have decreased by 48.8% and is now trading at $2.1350.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 16th 2023.
View our FUSN earnings forecast.

Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) posted its quarterly earnings data on Tuesday, November, 9th. The company reported ($0.45) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.58) by $0.13. The firm earned $0.33 million during the quarter. Fusion Pharmaceuticals had a negative net margin of 4,189.61% and a negative trailing twelve-month return on equity of 38.72%.

Based on aggregate information from My MarketBeat watchlists, some companies that other Fusion Pharmaceuticals investors own include Overstock.com (OSTK), U.S. Xpress Enterprises (USX), Camping World (CWH), DocuSign (DOCU), Pfizer (PFE), Pure Storage (PSTG), CrowdStrike (CRWD), Livongo Health (LVGO), NVIDIA (NVDA) and OPKO Health (OPK).

(FUSN) raised $126 million in an IPO on Friday, June 26th 2020. The company issued 8,400,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, Jefferies and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Fusion Pharmaceuticals trades on the NASDAQ under the ticker symbol "FUSN."

Fusion Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Federated Hermes Inc. (7.09%), RA Capital Management L.P. (1.47%), Point72 Asset Management L.P. (0.69%), Sofinnova Investments Inc. (0.27%), Tekla Capital Management LLC (0.23%) and UBS Group AG (0.13%). Insiders that own company stock include Adams Street Partners Llc, John Valliant, Johnson & Johnson and Steven Gannon.
View institutional ownership trends.

Shares of FUSN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of FUSN stock can currently be purchased for approximately $2.14.

Fusion Pharmaceuticals (NASDAQ:FUSN) has a market capitalization of $95.56 million and generates $1.44 million in revenue each year. The company earns $-81,050,000.00 in net income (profit) each year or ($1.85) on an earnings per share basis.

Fusion Pharmaceuticals' mailing address is 270 LONGWOOD ROAD SOUTH, HAMILTON A6, L8P 0A6. The official website for the company is fusionpharma.com. The company can be reached via phone at 289-799-0891 or via email at ir@fusionpharma.com.